Unlocking Hope: How Heat Therapy Might Shield Lungs from Radiation Damage in Cancer Treatment
Picture this: You're battling a tough thoracic cancer, undergoing radiation therapy that's saving your life – but at what cost to your lungs? Radiation pneumonitis, that painful inflammation of the lungs, looms as a scary side effect for many patients. It's the hidden enemy in the fight against cancers like lung or esophageal tumors. But what if we told you there's emerging evidence that adding heat – yes, hyperthermia – could slash the risk of this complication? Stick around, because this isn't just another study; it's a game-changer for how we think about combining treatments. And here's where it gets controversial: Could something as simple as controlled heating genuinely outshine traditional radiotherapy alone, or is this too good to be true?
Hyperthermia Links to Reduced Radiation Pneumonitis Risk Post-Thoracic Radiotherapy: Insights from a Retrospective Analysis
Research Article
Freely Accessible (via https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research)
Publication Date: November 8, 2025
Contributors:
Wentao Gao¹,²,
Jiafeng Liang¹,
Lingling Wang¹,⁴,
Yanyan Zhao³,
Shenglin Ma¹,⁵ &
Lucheng Zhu¹,⁴,⁵
BMC Cancer (https://bmccancer.biomedcentral.com/) volume 25, Article 1731 (2025) Cite this article
Abstract
Objective
This investigation explores the potential benefits of integrating radiotherapy with hyperthermia (RHT) in minimizing radiation pneumonitis (RP) among individuals diagnosed with thoracic malignancies. For newcomers to medical research, think of hyperthermia as a targeted heating technique that warms up cancerous tissues to make them more susceptible to other treatments, while RP is essentially lung inflammation triggered by radiation, which can range from mild coughing to severe breathing difficulties.
Methods
We reviewed records from 233 individuals treated for thoracic cancers between 2017 and 2020 at our institution. Patients were categorized based on their therapies: those who received RHT (n=114) versus those who had radiotherapy alone (RT, n=119). Monitoring spanned three months prior to treatment initiation and extended for six months afterward. We assessed and contrasted RP rates in both cohorts, focusing on how hyperthermia might influence outcomes.
Findings
For patients where the lung volume exposed to over 20 Gray (Gy) of radiation (V20 > 20%) – a measure indicating higher radiation doses to the lungs – the RHT group showed a 33.33% rate of grade ≥2 RP, compared to 55.32% in the RT group. This disparity was statistically notable (P=0.034). Additionally, the frequency of hyperthermia sessions correlated with RP rates (P=0.043). Through advanced statistical modeling, we identified gender, performance status (PS) score, and the number of hyperthermia treatments as key predictors of grade ≥2 RP risk.
Conclusion
Among those with V20 > 20%, hyperthermia appears to markedly lower the chances of developing grade ≥2 RP during thoracic radiotherapy. This could open doors to safer cancer care, but the real question is: Should hyperthermia become standard, or are we overlooking potential downsides?
Peer Review Reports (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15100-0/peer-review)
Introduction
Radiotherapy stands out as a cornerstone in managing thoracic cancers, especially for advanced cases of lung and esophageal tumors, where combining it with chemotherapy has become the go-to approach [1,2,3]. For those with locally advanced or oligometastatic lung cancer, thoracic radiation can extend life expectancy significantly. Yet, treatment fields often cover large areas due to the nature of these cancers. Even with cutting-edge precision techniques, RP incidence remains stubbornly high. Research indicates that grade ≥2 RP – moderate to severe lung reactions – can affect up to 30% of patients, with severe grade 3 or higher cases hitting 18% [4,5]. As more folks now benefit from targeted drugs and immunotherapies, pushing survival rates up by 60-70%, roughly the same percentage need thoracic radiation for lung or mediastinal spread [6]. The NICOLAS trial, for instance, reported an 11.7% rate of grade ≥3 RP when combining chemo-radiotherapy with the immunotherapy nivolumab [7].
When RP strikes, it not only derails follow-up therapies but also worsens overall prognosis and quality of life [8,9]. Currently, steroids are the main treatment, but high doses can undermine immunotherapy effectiveness. Clinicians rely on factors like lung function, tumor size, and radiation doses to predict RP, but accuracy is limited. Reducing RP is crucial, and that's where hyperthermia – applying heat to fight cancer – enters the scene.
Hyperthermia uses heat to target tumors, enhancing the effects of radiotherapy, chemotherapy, or even immunotherapies, particularly for resistant cancers. It boosts tumor sensitivity and control rates, leading to better outcomes [10]. It's already integrated into radiotherapy for various thoracic cancers with promising results. For example, Kuo et al. shared a remarkable case where chemoradiotherapy plus modulated electro-hyperthermia turned an inoperable stage IVB esophageal cancer into a resectable one [11]. Yeo described a stage IIIB lung cancer patient, too frail for standard chemo, who fared well with hyperthermia alongside radiotherapy [12].
Yet, studies on hyperthermia's ties to RP prevention are scarce. Wang et al. analyzed elderly esophageal cancer patients treated with intensity-modulated radiotherapy (IMRT) and found hyperthermia cut grade ≥2 RP rates [13]. While hyperthermia's role in boosting cancer treatment is established, its effects on lung inflammation are underexplored. This study probes whether hyperthermia protects against RP, providing data for future trials and promoting its use.
Materials and Methods
Study Participants
Eligible individuals had thoracic cancers like esophageal, lung, or thymoma, receiving at least 30 Gy of thoracic radiation. They needed CT scans three months before, during, and up to six months post-treatment, plus blood tests for complete blood count and C-reactive protein (CRP) – markers of inflammation – before and during therapy. We excluded those with stereotactic body radiation for metastases, post-surgery bed radiation, pre-existing pneumonitis, or re-irradiation. Patients were split into RHT (with hyperthermia) and RT (without) groups.
Radiotherapy Techniques
Radiation was delivered via an AXESSE linear accelerator (Elekta, Sweden), using IMRT, volume-modulated arc therapy (VMAT), and 4D image guidance. Tumor outlines (gross tumor volume or GTV) were drawn on CT scans. The clinical target volume (CTV) expanded 5 mm from the GTV, and the planning target volume (PTV) added 5-8 mm for breathing and setup errors. Critical structures like lungs, heart, esophagus, liver, and spine were protected. Doses ranged from 30.0 to 66.0 Gy, in 1.8-3.0 Gy daily fractions, five days a week.
Hyperthermia Procedure
We used the Jilin Maida NRL-003 endogenous field high-frequency system with dual frequencies (4068 MHz and 3570 MHz) and four electrode plates, outputting up to 5500 VA. Hyperthermia began on day one of radiation, twice weekly. Sessions were tailored to patient tolerance, maintaining tumor core temperatures at 41-43°C. Each session lasted 45-60 minutes once the target hit ≥41°C.
Defining Radiation Pneumonitis
Pneumonitis grading followed the Radiation Therapy Oncology Group (RTOG) criteria, tracking severity from grade 1 (mild) to higher levels. RP was diagnosed as lung inflammation within six months of radiation start, confirmed by symptoms and CT scans, reviewed by two senior oncologists for consensus.
Data Analysis
Using SPSS version 20 and R software (version 4.3.0), we analyzed data. Continuous data are presented as means with standard deviations or medians with ranges. Differences were tested with t-tests or Mann-Whitney U tests. Chi-square or Fisher's exact tests handled categorical data. Logistic regression included variables with P<0.2 from initial analyses. All tests were two-sided.
Results
Participant Demographics
From April 2017 to March 2020, we screened 293 records from Hangzhou Cancer Hospital, enrolling 233 after excluding 60 with incomplete data (see Figure 1). The group was predominantly male (85.84%, n=200), with a median age of 65.15 ± 10.25 years (range 32-88). Median PTV dose was 54.0 Gy (30.0-66.0 Gy), and average lung V20 was 17.85 ± 7.03%. Details by treatment group are in Table 1.
[Study Flowchart]
Full size image (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15100-0/figures/1)
[Table 1: Detailed Characteristics]
Full size table (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15100-0/tables/1)
Radiation Pneumonitis Rates Across Groups
In the RHT group (n=114), 95 cases (83.33%) developed RP, including 46 (40.35%) grade ≥2. The RT group (n=119) had 104 cases (87.39%), with 51 (42.86%) grade ≥2. No significant differences in overall or grade ≥2 RP rates (P>0.05). See Table 2.
[Table 2: RP Incidence]
Full size table (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15100-0/tables/2)
To dig deeper, we examined V20's role separately in each group. In RT patients, grade ≥2 RP hit 55.32% when V20>20% versus 34.29% when ≤20% (P<0.05). In RHT, rates were 33.33% and 35.42%, with no significant difference. See Table 3.
[Table 3: RP by V20 Levels]
Full size table (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15100-0/tables/3)
Focusing on High V20 Patients
For those with V20>20%, we compared RP grades. RHT (n=45) had 38 RP cases: 23 grade 1, 13 grade 2, 2 grade 3, 0 grade 4. RT (n=47) had 44 cases: 18 grade 1, 22 grade 2, 4 grade 3, 0 grade 4. Overall RP differed (P=0.025), and grade ≥2 RP was lower in RHT (15 cases vs. 26, 33.33% vs. 55.32%, P=0.034). See Table 4.
[Table 4: RP in V20>20% Subgroup]
Full size table (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15100-0/tables/4)
Hyperthermia Frequency's Influence
Among V20>20% patients, we analyzed RP by hyperthermia sessions. For 0-2 sessions (n=50), grade <2 RP was 44.00%, grade ≥2 was 56.00%. For 3-7 sessions (n=7), 57.14% and 42.86%. For ≥8 sessions (n=35), 71.43% and 28.57%. More sessions correlated with declining grade ≥2 RP (P=0.043). See Figure 2.
[The Effect of Hyperthermia Sessions on RP]
Full size image (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15100-0/figures/2)
Statistical Insights
Univariate analysis linked hyperthermia frequency to RP severity (P=0.014). Multivariate logistic regression showed gender (OR=0.11, P=0.012), PS score (OR=0.36, P=0.047), and ≥8 sessions (OR=0.27, P=0.008) as independent grade ≥2 RP factors. See Table 5.
[Table 5: Analysis Results]
Full size table (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15100-0/tables/5)
Discussion
Hyperthermia is widely used in cancer care [14,15], but its RP connections are understudied. Our findings suggest it lowers grade ≥2 RP in high-dose radiation settings, potentially revolutionizing treatment plans.
Combining radiotherapy with hyperthermia amplifies cancer-fighting power. Huilgol et al.'s phase III trial with 54 head and neck cancer patients found hyperthermia boosted complete response rates from 42% to 79% [16]. Dong et al. reported reduced recurrence and mortality in liver cancer patients with added hyperthermia [17]. These show synergy, but we must weigh side effects and refine protocols.
In our RT-only V20>20% group, grade ≥2 RP was 55.3%, matching prior studies (52.4% for V20<30% [18], 51% for 26-30% [19]). When no dosimetric limits applied, hyperthermia's benefits weren't apparent, likely because low RP risk obscured effects, as Boonyawan et al. noted RP drops to 6% with V10<30% and V20<20% [20].
Our data indicates hyperthermia reduces grade ≥2 RP in V20>20% patients, perhaps by mitigating V20 impacts. In RT, higher V20 raised RP (55.32% vs. 34.29%, P=0.024), but not in RHT. More sessions decreased severe RP, suggesting cumulative protection.
Interestingly, RHT had higher grade <2 RP but lower ≥2, possibly due to hyperthermia stimulating matrix metalloproteinases (MMPs) for tissue repair without fibrosis [21]. Or, some ≥2 cases downgraded post-treatment.
Mechanistically, hyperthermia may protect by inducing heat shock proteins (HSPs) like HSP70, which aid DNA repair and reduce lung injury [22-27]. Improved blood flow clears inflammatory mediators, preventing cytokine storms [28-29]. HSPs' transient nature means repeated sessions sustain effects.
Critically, HSP70 might hinder apoptosis, potentially weakening treatment [28]. Its effects fade quickly [29], underscoring the need for scheduled hyperthermia.
Limitations include retrospective design, unbalanced baselines, and small subgroups, prompting larger, prospective studies.
Conclusions
For V20>20% patients, hyperthermia cuts grade ≥2 RP, with lower rates as sessions increase. Gender, PS, and session count influence outcomes, paving the way for tailored therapies.
Data Availability
Raw data are in the article; contact corresponding authors for inquiries.
Abbreviations
RHT: Radiotherapy plus Hyperthermia
RP: Radiation Pneumonitis
HT: Hyperthermia
CRP: C-reactive protein
RTOG: Radiation Therapy Oncology Group
CTV: Clinical Target Volume
GTV: Gross Tumor Volume
PTV: Planning Target Volume
HSPs: Heat Shock Proteins
RT: Radiotherapy
CI: Confidence Interval
IMRT: Intensity Modulated Radiotherapy
VMAT: Volume Modulated Arc Therapy
SD: Standard Deviation
OR: Odds Ratio
MMPs: Matrix Metalloproteinases
References
[List of references, identical to original]
Acknowledgments
None.
Funding
Supported by grants from The Youth Science and Technology Innovation Training Project of Hangzhou Cancer Hospital (HZCH2021QN01), The Construction Fund of Key Medical Disciplines of Hangzhou (2025HZGF06), and National Natural Science Foundation of China (82373889). Funders had no input.
Author Information
Affiliations as in original.
Contributions
As in original.
Ethics Declarations
As in original.
But here's the part most people miss: While hyperthermia shows promise, is it universally safe? Could it interact poorly with certain drugs or exacerbate other side effects? What if this study overlooks long-term lung scarring? Do you think hyperthermia deserves a spot in standard cancer protocols, or should we demand more trials before jumping in? Share your thoughts in the comments – does this excite you or raise red flags?
